ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02433093
Recruitment Status : Completed
First Posted : May 4, 2015
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

April 29, 2015
May 4, 2015
November 2, 2016
April 2015
September 2015   (Final data collection date for primary outcome measure)
  • Safety: Incidence of adverse events (AEs) [ Time Frame: Up to 10 weeks ]
  • Safety: Suicidality as assessed using the Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Up to 10 weeks ]
  • Safety: Sleep habits as assessed using a participant-recorded sleep diary [ Time Frame: Up to 21 days ]
Same as current
Complete list of historical versions of study NCT02433093 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics: Maximum plasma concentration (Cmax) [ Time Frame: Post dose on Day 1 and Day 22 (or final dose) ]
  • Pharmacokinetics: Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) [ Time Frame: Post dose on Day 1 ]
  • Pharmacokinetics: Area under the plasma concentration-time curve over the dosing interval (AUC0-tau) [ Time Frame: Post dose on Day 22 (or final dose) ]
  • Pharmacokinetics: Time to maximum plasma concentration (Tmax) [ Time Frame: Post dose on Day 1 and Day 22 (or final dose) ]
  • Pharmacokinetics: Trough plasma concentration (Ctrough) [ Time Frame: Post dose on Day 1 and Day 22 (or final dose) ]
  • Pharmacokinetics: Apparent terminal elimination half-life (t1/2) [ Time Frame: Post dose on Day 22 (or final dose) ]
  • Safety: QT interval corrected using the Fridericia method (QTcF) [ Time Frame: Up to 10 weeks ]
Same as current
Not Provided
Not Provided
 
A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)
A Single-Center, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose, Semi-Sequential Adaptive Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Basimglurant Following Oral Administration in Healthy Subjects and in Patients With Major Depressive Disorder
The study will assess the safety, tolerability, and pharmacokinetics of basimglurant compared to placebo after multiple ascending oral doses for up to 22 days in healthy subjects and in patients with MDD on stable selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) background therapy.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Major Depressive Disorder, Healthy Volunteer
  • Drug: Basimglurant
    Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
  • Drug: Placebo
    Participants will receive 22 days of once-daily oral matching placebo capsules.
  • Experimental: Basimglurant: Healthy Cohort (1)
    Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
    Intervention: Drug: Basimglurant
  • Experimental: Basimglurant: Healthy Cohort (2)
    Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
    Intervention: Drug: Basimglurant
  • Experimental: Basimglurant: Healthy Cohort (3)
    Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
    Intervention: Drug: Basimglurant
  • Experimental: Basimglurant: Healthy Cohort (4)
    Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
    Intervention: Drug: Basimglurant
  • Experimental: Basimglurant: MDD Cohort (5)
    Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
    Intervention: Drug: Basimglurant
  • Placebo Comparator: Placebo: Healthy Cohorts (1 to 4)
    Healthy participants will receive a 22-day regimen of matching placebo capsules.
    Intervention: Drug: Placebo
  • Placebo Comparator: Placebo: MDD Cohort (5)
    Participants with MDD will receive a 22-day regimen of matching placebo capsules.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
56
60
September 2015
September 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 to 65 years of age, inclusive
  • Body weight at least 50 kg
  • Healthy male or female subjects (Healthy Cohorts)
  • Body mass index (BMI) 18 to 30 kg/m^2, inclusive (Healthy Cohorts)
  • Nonsmoker for at least 90 days prior to dosing (Healthy Cohorts)
  • Primary diagnosis of MDD without psychotic features (MDD Cohort)
  • BMI 18 to 35 kg/m^2, inclusive (MDD Cohort)
  • Current partial response to ongoing SSRI or SNRI antidepressant treatment at an adequate dose and for at least 4 weeks (MDD Cohort)
  • Clinical Global Impression of Severity (CGI-S) score 3 or greater (MDD Cohort)
  • Other regimens stable for at least 8 weeks prior to screening (MDD Cohort)

Exclusion Criteria:

  • Pregnant or lactating women
  • History of alcohol or substance abuse in the past 6 months
  • Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
  • Clinically relevant electrocardiogram (ECG) abnormalities or a personal or family history of congenital long QT syndrome
  • Participation in an investigational study within 90 days of screening
  • Blood donation over 500 mL within 3 months of screening
  • Hypersensitivity to any study medication or excipients
  • Psychotic symptoms or comorbid mood disorder
  • Significant suicide risk
  • Major illness within 1 month before screening, or febrile illness within 1 week (Healthy Cohorts)
  • Average alcohol consumption of more than 2 units per day (Healthy Cohorts)
  • Multi-drug therapy for depression including antidepressants or adjunctive medications (MDD Cohort)
  • Prior use of basimglurant (MDD Cohort)
  • Cigarette use of greater than 1 pack per day (MDD Cohort)
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02433093
NP29583
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP